AI Summary

Researchers at Ben-Gurion University of the Negev (BGU) have identified how two different classes of medication—the GLP-1 receptor agonist semaglutide and the anti-inflammatory drug colchicine—act on the heart to prevent the development of Atrial Fibrillation (AF). The study, published in Europace, provides a clearer biological map of how these drugs protect the heart's structure and electrical signaling, potentially offering new ways to treat patients before AF takes hold.

AI summaries can be wrong sometimes—always verify important details using the source article.